
    
      The study will enroll approximately 366 participants. Participants will be randomly assigned
      to one of the two treatment groups in 1:1 ratio:

        1. Actovegin

        2. Placebo (dummy inactive substance) - this is a tablet/intravenous infusion that looks
           like the study drug but has no active ingredient

      All participants will be asked to take intravenous infusion for 2 weeks followed by oral
      tablets for 10 weeks.

      This multi-center trial will be conducted Russia, Georgia, and Kazakhstan. The overall time
      to participate in this study is 25 to 26 weeks. Participants will make multiple visits to the
      clinic, and 12 weeks after last dose of study drug for a follow-up assessment.
    
  